Genetic imaging study with [Tc-99m] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate
| Autor: | Burak Baykara, Ali Saffet Gonul, Neslihan İnal Emiroğlu, Türkan Ertay, Sefa Kizildag, Hatice Durak, Samet Kose, Sevay Alşen Güney, Aynur Pekcanlar Akay, Kaya Oguz, Dua Özsoylu, Duygu Keskin, Süha Miral, Luis Augusto Rohde, Gamze Çapa Kaya, Çiğdem Eresen Yazıcıoğlu, Handan Özek Erkuran, Mine Şencan Eren |
|---|---|
| Přispěvatelé: | HKÜ, 0- Bölüm Yok |
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Tc-99m-TRODAT-1 OROS-methylphenidate Oros methylphenidate 03 medical and health sciences 0302 clinical medicine Internal medicine mental disorders Severity of illness medicine ADHD DAT1 gene Allele Biological Psychiatry [Tc-(99m)] TRODAT-1 SPECT Pharmacology business.industry Putamen Imaging study 030227 psychiatry nervous system Attention deficit Clinical Global Impression business 030217 neurology & neurosurgery |
| Zdroj: | Progress in Neuro-Psychopharmacology and Biological Psychiatry. 86:294-300 |
| ISSN: | 0278-5846 |
| Popis: | WOS: 000436416800034 #REF! Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT. Dokuz Eylul University Research CommitteeDokuz Eylul University [2008132]; Fogarty MH/DD program; Institute of Nuclear Energy Research (INER-Taipei, Taiwan) This study was partially supported by Dokuz Eylul University Research Committee (2008132), Fogarty MH/DD program and the Institute of Nuclear Energy Research (INER-Taipei, Taiwan). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect